Half-Year 2022 Financial and Clinical Trials Update
NME submissions and their additional indications
Projects in phase II and III
RG6026
glofitamab + chemo
2L DLBCL
Roche
RG6026
New Molecular Entity (NME)
Additional Indication (AI)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
RG6058
glofitamab + chemo
1L ctDNA+ high risk
DLBCL
tiragolumab + T
1L PD-L1+ cervical
RG6180
autogene cevumeran
1L melanoma
bepranemab
RG6416
zinpentraxin alfa
Alzheimer's
alogabat
RG6354
(PRM-151)
RG7816
(GABA Aa5 PAM)
cancer
myelofibrosis
ASD
tiragolumab + T
Lunsumio (mosun) +
Other
RG6058 locally adv esophageal
RG7828
lenalidomide
RG7845
fenebrutinib
RMS
cancer
2L FL
Lunsumio (mosun) +
RG6058
ā Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
PDS-Port Delivery System with ranibizumab
Mosun-mosunetuzumab
*IONIS managed
tiragolumab +T
1L non-sq NSCLC
RG7828
Polivy
2L+ DLBCL (US)
RG7845
fenebrutinib
PPMS
astegolimab
RG6058
tiragolumab + T
1L PD-L1+mSCCHN
RG6149
(anti-ST2)
COPD
RG7906
ralmitaront
schizophrenia
tiragolumab+T+/-
RG6058
chemo
NSCLC neoadj/adj
RG6299+
ASO factor B
IgA nephropathy
RG7935
prasinezumab
Parkinson's
RG6058
tiragolumab + T
Stage III unresectable
RG6107
crovalimab
sickle cell disease
RG7907/
RG7854/
TLR7 ago (3)/CPAM (2)
/siRNA/PDL1 LNA
RG6321
RG6346/
Susvimo
(PDS)
1L NSCLC
RG6084
HBV
WAMD, 36-week refill
RG6026
glofitamab
3L+ DLBCL ā
RG6058
tiragolumab + T
1L PD-L1+ NSCLC
RG6107
crovalimab
aHUS
RG6139
PD1xLAG3
solid tumors
gantenerumab
RG1450
RG6147
early Alzheimer's
tiragolumab +T
RG6058
1L esophageal cancer
(CN)
RG6321
Susvimo
(PDS)
RG6114
inavolisib
(mPI3K alpha inh)
RG6171
giredestrant
(SERD)
semorinemab
galegenimab
(HtrA1)
NME
geographic atrophy
RG6100
RG6179
Alzheimer's
DME
DME
Susvimo
1L HR+ BC
1L ER+/HER2-mBC
crovalimab
zinpentraxin alfa
giredestrant
brain shuttle
RG6107
RG6321
PNH (CN)
gantenerumab
RG1450
prodromal to mild
RG7716
(PDS)
DR (US)
Vabysmo
(faricimab)
RG6354
(PRM-151)
RG6171
(SERD)
RG6102
IPF
delandistrogene
ER+ BC adj
giredestrant (SERD) +
gantenerumab
Alzheimer's
latent myostatin +
RG6299+
ASO factor B
geographic atrophy
NME
RG6356
Alzheimer's
BRVO/CRVO
moxeparvovec
(SRP-9001) DMD
RG6171
Phesgo
RG6237
1L ER+/HER2+ BC
Evrysdi
SMA
RG7774
retinal disease
2022
2023
2024
2025 and beyond
Status as of July 21, 2022
76View entire presentation